Clinical trials: Asthma in Children
Asthma, Allergic Rhinitis
Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)
The purpose of this study is to assess real-world effectiveness of montelukast in children (2 to 14 years) with asthma and allergic rhinitis.
- Trial name
- NCT00442559
- Testing
- montelukast sodium, inhaled corticosteroid
- Volunteers
- 191 people
- Sponsor
- Organon and Co
Asthma
Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma
This study is being conducted to compare the pharmacodynamics (bronchodilation, onset and duration of action), of a single dose of formoterol fumarate in combination with mometasone furoate to placebo in children of 5-11 years…
- Trial name
- NCT00746330
- Testing
- Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D)
- Where
- 9 sites in United States, Colombia and 1 more
- Volunteers
- 32 people
- Sponsor
- Novartis
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over 48 weeks, compared to placebo, in children…
- Trial name
- NCT01634139
- Testing
- Tiotropium low dose QD, Tiotropium high dose QD
- Where
- 79 sites in United States, Bulgaria and 14 more
- Volunteers
- 403 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
This purpose of the study is to investigate the bronchodilating effects of 3 different dosages of formoterol given in combination with budesonide as Symbicort pMDI.
- Trial name
- CHASE 2 (NCT01136655)
- Testing
- 80/2.25 μg Symbicort pMDI, 80/4.5 μg Symbicort pMDI, Foradil Aerolizer 12 μg
- Where
- 34 sites in United States, Bulgaria and 4 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Asthma
Safety and Blood Level Study of Unit Dose Budesonide
The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in healthy volunteers.
- Trial name
- UDB P101 (NCT00627679)
- Testing
- Budesonide Inhalation Suspension, MAP0010 low dose, MAP0010 intermediate dose
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Allergan
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Rhinoconjunctivitis, Rhinitis
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00550550
- Testing
- SCH 697243, Loratadine Syrup 1 mg/mL Rescue Treatment, Loratadine 10 mg Rescue Treatment
- Volunteers
- 345 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Seasonal
Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
The purpose of this study is to assess the efficacy and safety of short ragweed pollen allergen extract (MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced…
- Trial name
- NCT02478398
- Testing
- Short ragweed pollen allergen extract, Self-injectable epinephrine, Albuterol/Salbutamol
- Volunteers
- 1,025 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
- Trial name
- TRAILHEAD (NCT04673630)
- Testing
- Tezepelumab
- Where
- 6 sites in Hungary, South Africa and 1 more
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Asthma
A Dose-ranging Study of Fluticasone Furoate (FF)
This is a Phase IIb, multi-centre, stratified, randomised, double-blind, double-dummy, parallel-group, placebo and active controlled study in children aged 5-11 years with persistent uncontrolled asthma.
- Trial name
- NCT01563029
- Testing
- Fluticasone Furoate, Fluticasone Propionate
- Where
- 139 sites in United States, Bulgaria and 13 more
- Volunteers
- 597 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study of 2 Doses of MAP0010 in Asthmatic Children
The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.
- Trial name
- NCT00697697
- Testing
- 0.135mg MAP0010, 0.25mg MAP0010
- Volunteers
- 192 people
- Sponsor
- Allergan
Asthma
Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma
This study is designed to explore lung function effects of two doses of indacaterol acetate, 75 μg and 150 μg, in pediatric asthma patients 6-11 years old, and to compare the systemic exposure to indacaterol in plasma with…
- Trial name
- NCT02892019
- Testing
- Indacaterol acetate 75 μg, Indacaterol acetate 150 μg
- Where
- 29 sites in Belgium, Colombia and 9 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification
This study consists of a 3-year double-blind phase during which patients will receive atopic dermatitis (AD) treatment either with pimecrolimus cream 1% long-term management (LTM) or with a conventional corticosteroid-based…
- Trial name
- NCT00124709
- Testing
- Pimecrolimus, Corticosteroid
- Where
- 36 sites in United States
- Volunteers
- 1,091 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years with Asthma during 12…
- Trial name
- CHASE 3 (NCT02091986)
- Testing
- Symbicort pMDI, Budesonide pMDI
- Where
- 70 sites in United States, Mexico and 2 more
- Volunteers
- 882 people
- Sponsor
- AstraZeneca
Asthma
Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable asthma and evaluate the pharmacokinetic…
- Trial name
- NCT00995904
- Testing
- 84ug MAP0020, 42ug MAP0020, 21ug MAP0020
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Allergan
Asthma
To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.
To compare the pharmacokinetics of budesonide delivered by BDA MDI to budesonide delivered by Pulmicort Respules in children with Asthma aged 4 to 8 years.
- Trial name
- BLANC (NCT04848662)
- Testing
- BDA MDI (PT027) 160/180 μg, Pulmicort Respules 0.5 MG/ML Inhalation Suspension
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Bond Avillion 2 Development LP
Asthma
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo
This purpose of the study is to investigate if budesonide pMDI 160 �g twice a day during 6 weeks is effective and safe in treating asthmatic children aged 6 to <12 years
- Trial name
- CHASE 1 (NCT01136382)
- Testing
- budesonide
- Where
- 87 sites in United States, Bulgaria and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Asthma
Evaluation of Dupilumab in Children With Uncontrolled Asthma
Primary Objective: To evaluate the efficacy of dupilumab in children 6 to less than (<) 12 years of age with uncontrolled persistent asthma.
- Trial name
- VOYAGE (NCT02948959)
- Testing
- Dupilumab, Asthma Controller Therapies, Asthma Reliever Therapies
- Where
- 99 sites in United States, Argentina and 16 more
- Volunteers
- 408 people
- Sponsor
- Sanofi
Asthma
Albuterol HFA MDI in Pediatric Participants With Asthma
The primary objective of this study is to evaluate the chronic-dose and efficacy of Albuterol-HFA-MDI relative to placebo in pediatric asthmatics.
- Trial name
- NCT00577655
- Testing
- Albuterol, Proventil® HFA
- Where
- 13 sites in United States
- Volunteers
- 103 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma
This study will include the patients who are Japanese children with bronchial asthma aged 5 years to 15 years old and have completed the Phase III study (Study code: D5254C00769) at about 29 centres.
- Trial name
- NCT00509028
- Testing
- Budesonide, Conventional Asthma Therapy
- Where
- Japan
- Volunteers
- 241 people
- Sponsor
- AstraZeneca